Fever with Rash
Chooi Yuo Hao (Eugene)
Fe
ver
With
Ra
sh
1
•Varicella Zoster Virus (VZV)•Perinatally acquired varicella
•Kawasaki Disease
2
Fe
ver
With
Ra
sh
History Taking• Introduction• Chief complaints• HOPI• Past history (Medical and Surgical)• Birth history• Feeding history• Developmental history• Immunization history• Drug history• Family history• Social and environmental history
3
Fe
ver
With
Ra
sh
Physical examination• General examination• Systemic examination
4
Fe
ver
With
Ra
sh
Varicella Zoster Virus (VZV)• 1 of the known human herpes viruses
• Varicella Zoster Virus (VZV) – Chicken Pox• Herpes Zoster – Shingles
• Neurotropic human herpes virus with similarities to herpes simplex virus
• Air-borne and highly contagious disease• Causes primary, latent and recurrent infections• Increased morbidity and mortality in adolescent,
adults, and immunocompromised persons• Predisposed to severe group A streptococcus and
Staphylococcus aureus infection
Fe
ver
With
Ra
sh
5
• Prodromal symptoms• Nausea, loss of appetite, aching muscle and headache
• Fever (mostly low grade), malaise, 24-48hrs later associated with vesicular rash (successive crops of pruritic vesicles that evolve to pustules, crusts and at times scar4)
• Rashes starts from the scalp, face or trunk, upper extremities and lower extremities
• Some children might not have prodromal symptoms, they begins with vesicular rash and fever
6
Fe
ver
With
Ra
sh
Clinical Manifestation
7
Fe
ver
With
Ra
sh
Varicella lesion
8
Fe
ver
With
Ra
sh
Vesicular rash of chicken pox
9
Fe
ver
With
Ra
sh
Haemorrhagic chickenpox
Complications• Bacterial superinfection
• Staphylococcal• Streptococcal• May lead to toxic shock syndrome or necrotizing fasciitis
• Central nervous system• Generalized encephalitis• Aseptic meningitis
• Immunocompromised• Haemorrhagic lesions• Pneumonitis • Progressive and disseminated infection• Disseminated intravascular coagulation
10
Fe
ver
With
Ra
sh
Treatment• Antiviral treatment – Acyclovir • Human varicella zoster immunoglobulin (ZIG) is
recommended for high-risk immunosuppressed individuals
11
Fe
ver
With
Ra
sh
Prognosis• Quite good excluded immunosuppressed patients• Resolves spontaneously – self limited• Mortality rate 2-3 per 100,000 cases
12
Fe
ver
With
Ra
sh
Prevention• Difficult to prevent as the infection is highly
contagious for 24-48 hour before the rash appears.• Live attenuated VZV vaccine can be administer• Postexposure prophylaxis – VZV vaccine or oral
acyclovir
13
Beware of admitting a chickenpox contact to a clinical area with
immunocompromised children
Fe
ver
With
Ra
sh
Perinatally Acquired Varicella• Maternal infection (onset of rash) within 5 days
before and 2 days after delivery• Mortality rate is high, due to severe pulmonary
disease or widespread necrotic lesions of viscera• The production and transplacental passage of
maternal antibodies that modify the course of illness in new-borns
• Exposed susceptible women can be protected with varicella zoster immune globulin (VZIG) and treated with acyclovir.
14
Fe
ver
With
Ra
sh
• Women with varicella lesions should be isolated from their newborns, breast feeding is contraindicated; when all the lesions have crusted, breast feeding should be commence
• Neonates with varicella lesions should be isolated from other infants but not from their mothers.
• Infants born in the high-risk period should also receive zoster immune globulin and are often also given acyclovir prophylactically
15
Fe
ver
With
Ra
sh
Summary• Primary, latent and recurrent infections• Primary infection is manifested as varicella – chickenpox• Results in establishment of a lifelong latent infection of
sensory ganglion neurons• Reactivation of the latent infection causes herpes zoster –
shingles• Increase morbidity and mortality in adolescents, adults and
immunocompromised persons, and predisposes to severe group A streptococcus and Staphylococcus aureus infections
• Can be treated with antiviral drugs• Initial infection can be prevented by immunization with live-
attenuated VZV vaccine16
Fe
ver
With
Ra
sh
Kawasaki Disease• Also known as acute febrile mucocutaneous
syndrome• A systemic febrile condition affecting children
usually <5 years old• Aetiology remains unknown, possible bacterial
toxins or viral agents with genetic predisposition• Aneurysms of the coronary arteries are an important
complication• Affects children 6 months – 4 years old, with a peak
at the end of the first year17
Fe
ver
With
Ra
sh
Diagnostic criteria• Exclusive diagnosis• Fever (HGF, remittent and unresponsive to antibitics)
lasting at least 5 days• At least 4 out of 5 of the following
• Bilateral non-purulent conjunctivitis• Mucosal changes of the oropharynx (injected pharynx, red
lips, dry fissured lips, strawberry tongue)• Change in extremities (oedema and/or erythema of the
hands or feet desquamation, beginning periungually)• Rash (usually truncal), polymorphous but not vesicular• Cervical lymphadenopathy
• Illness not explained by other disease process18
Fe
ver
With
Ra
sh
19
Fe
ver
With
Ra
sh
Red, cracked lips and conjunctiva inflammation
20
Fe
ver
With
Ra
sh
Congestion of bulbar conjunctiva
21
Fe
ver
With
Ra
sh
Strawberry tongue
22
Fe
ver
With
Ra
sh
Peeling of fingers
23
Fe
ver
With
Ra
sh
Desquamation of the fingers
24
Fe
ver
With
Ra
sh
Indurative edema
Other helpful signs• Indurated BCG scar• Perianal excoriation, irritability• Altered mental state• Aseptic meningitis• Transient arthritis• Diarrhoea, vomiting, abdominal pain• Hepatoslenomegaly• Hydrops of gallbladder• Sterile pyuria
25
Fe
ver
With
Ra
sh
Investigation• Full blood count
• Anaemia, leukocytosis, thrombocytosis
• ESR and CRP elevated• Serum albumin <3gdl; Raised alanine
aminotrasaminase (ALT)• Urine > 10 wbc/hpf• Chest x-ray, ECG• Echocardiogram in the acute phase and repeat at
6-8 weeks or earlier if indicated
26
Fe
ver
With
Ra
sh
27
Fe
ver
With
Ra
sh
Coronary angiogram demonstrating giant aneurysms of the LAD with obstruction and giant aneurysms of the RCA with
area of severe narrowing
Complication• Coronary vasculitis, usually within 2 weeks of
illness• Asymptomatic
• Myocardial infection• Myocardial infarction• Pericarditis• Myocarditis• Endocarditis• Heart failure• Arrhythmias
28
Fe
ver
With
Ra
sh
• Incomplete Kawasaki Disease (kindly refer to the 2nd edition of paeds protocol pg 115)
• Atypical Kawasaki Disease (kindly refer to the 2nd edition of paeds protocol pg 115)
29
Fe
ver
With
Ra
sh
30
Fe
ver
With
Ra
sh
Evaluation of Suspected Incomplete Kawasaki Disease
Treatment • Primary treatment
• IV Immunoglobulins 2 Gm/kg infusion over 10-12 hoursTherapy <10 days of onset effective in preventing coronary vascular damage
• Oral Aspirin 30 mg/kg/day for 2 weeks or until patient is afebrile for 2-3 days
31
Fe
ver
With
Ra
sh
Maintenance• Oral Aspirin 3-5 mg/kg daily (anti-platelet dose) for
6-8 weeks or until ESR and platelet count normal
If coronary aneurysm present, then continue aspirin until resolves
Alternative: Oral Dipyridamole 3-5mg/kg daily
32
Fe
ver
With
Ra
sh
Prognosis• Complete recovery in children without coronary
artery involvement• Most (80%) 3-5mm aneurysm resolve
• 30% of 5-8mm aneurysm resolve
• Prognosis worst for aneurysms > 8mm; mortality 1~2%
• Good prognosis for aneurysms <4mm
33
Fe
ver
With
Ra
sh
Summary • Mainly affects infants and young children• The diagnosis is made on clinical features such as• Fever lasting at least 5 days• At least 4 out of 5 of the following
• Bilateral non-purulent conjunctivitis• Mucosal changes of the oropharynx (injected pharynx, red lips, dry
fissured lips, strawberry tongue)• Change in extremities (oedema and/or erythema of the hands or feet
desquamation, beginning periungually)• Rash (usually truncal), polymorphous but not vesicular• Cervical lymphadenopathy
• Complications – Coronary artery aneurysms and sudden death
• Treatment – Intravenous immunoglobulin and aspirin
34
Fe
ver
With
Ra
sh
References • Hussein Imam, Ng H.P., Thomas T. (2008). Paediatrics
Protocols for Malaysian Hospitals (2nd edition): pg 6,78,115-116
• Lissauer T., Clayden G. (2007). Illustrated textbook of Paediatrics (3rd edition): pg 230-232, 237-238
• Kliegman R.M., Beherman R.E., Jenson H.B., Stanton B.F. (2007). Nelson textbook of Paediatrics (18th edition)
• Klaus W., Richard A.J. (2009). Fitzpatrick’s Color Atlas & Synopsis of Clinical Dermatology (6th edition): pg 833
• Kliegman R.M., Marcdante K.J., Beherman R.E., Jenson H.B. (2007). Nelson Essentials of Paediatrics (5th edition): pg 470-472
35
Fe
ver
With
Ra
sh
36
Fe
ver
With
Ra
sh